WEST LAFAYETTE, Ind., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the Company's scientific management team has been selected by the American Chemical Society as the recipient of the 2015 George and Christine Sosnovsky Award for Cancer Research.
The award, sponsored by the George and Christine Sosnovsky Endowment Fund, aims to recognize outstanding achievements in the elucidation of the chemical and biochemical pathways underlying human cancers, leading to the discovery and development of improved cancer therapeutics.
Chief Science Officer, Dr. Philip S. Low, along with Dr. Christopher P. Leamon, vice president of research and development, Dr. Iontcho R. Vlahov, vice president of discovery chemistry, and Dr. Joseph A. Reddy, director of pharmacology, have been recognized because of their pioneering research on the use of small molecule ligand-targeting to selectively deliver highly cytotoxic therapeutic and imaging agents to tumors.
"We are extremely honored to receive this prestigious research award from the American Chemical Society," Dr. Low said. "This recognition highlights our unique approach of using small molecule targeting ligands to selectively deliver more potent therapeutic agents to a variety of tumor types, which we feel has the potential to provide an important treatment option for cancer patients. We'd like to thank our team at Endocyte for all of their contributions toward this important research, and look forward to continuing our work on SMDC candidates in the years ahead."
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte's website at www.endocyte.com.
CONTACT: Stephanie Ascher, Stern Investor Relations, Inc. (212) 362-1200, firstname.lastname@example.org